Platform FoR European Preparedness Against (Re-)emerging Epidemics- Australia
Funder
National Health and Medical Research Council
Funding Amount
$386,463.00
Summary
Infectious diseases rank high among the threats to human wellbeing and prosperity- globalisation, migration, tourism, intensive farming and changing climate enhance the likelihood of emergence of outbreaks of infectious disease. The optimal response to an emerging infectious disease requires the rapid acquisition of new knowledge. This project ensures that Australia can contribute to globally coordinated research that will meet the research challenge associated with any new pandemic infection.
Determining The Clinical Effectiveness Of Antiviral Drugs Against Oseltamivir- And Laninamivir-resistant Influenza Viruses In Animal Models
Funder
National Health and Medical Research Council
Funding Amount
$388,067.00
Summary
Currently, the neuraminidase inhibitors are the only drugs that are effective against seasonal influenza viruses. However, viruses can develop resistance to these drugs. Using viruses with varied levels of resistance, the project will determine the effectiveness of different drug treatments in animal models. This will lead to better treatment for those patients seriously ill with drug-resistant influenza viruses.
Boosting Effectiveness Of New Vaccines For Dengue ,HFMD And Influenza By Targeting Vaccine Antigens To Clec9A On Dendritic Cells.
Funder
National Health and Medical Research Council
Funding Amount
$396,332.00
Summary
Australian and Singapore laboratories will collaborate to develop improved vaccines against virus diseases, particularly Dengue, Hand Foot and Mouth Disease and Influenza. A novel technology will be used, the targeting of vaccines to a receptor on the surface of the dendritic cells that control immune responses. This will be used to boost responses to a series of vaccine candidates that are otherwise insufficiently immunogenic.